Global Human Fibrinogen Concentrate Market Size Likely to Grow at a CAGR of 11.3% By 2035

It is estimated that the market size of the global human fibrinogen concentrate will be USD 0.958 billion in 2025 and it is further estimated that the market size of the global human fibrinogen concentrate will increase to USD 1.06 billion in 2026 and reach approximately USD 2.78 billion in 2035 with the annual CAGR of 11.3% in the year 2026-2035.

Human fibrinogen concentrate Market Revenue and Trends

The human fibrinogen concentrate is an example of a market undergoing robust growth due to the rising rate of bleeding disorders like congenital fibrinogen deficiency, hemorrhage during trauma, and bleeding complications during surgery. The concentrates are very important in the restoration of fibrinogen levels and the effective formation of blood clot, which is why they are necessary in emergency care, trauma management, and complex surgical operations. Market growth is also increasing due to an increasing need of specific and fast-acting hemostatic therapies. Also, the development of new technologies in purification of plasma-derived products and better safety profiles is increasing clinical adoption. The rising number of surgical operations, growing awareness of the rare bleeding disorders and the growth of the healthcare infrastructure are all in favor of a long-term growth in the market throughout the forecast period.

What are the Factors that Significantly Exert an Influence on the development of Human fibrinogen concentrate Market?

The increase in the market of human fibrinogen concentrate is largely determined by the increase in the rates of traumas, surgical surgeries, and genetic disorders of bleeding as afibrinogenemia and hypofibrinogenemia. Fibrinogen concentrates are becoming more popular among healthcare providers compared to the traditional blood products such as cryoprecipitate because they are standardized and can be administered rapidly, and are less likely to cause transmission of pathogens. Such a transformation is being very beneficial to patient outcomes in the critical care environment.

The other significant aspect that has spurred the growth of the market is the ongoing improvement in the processes of plasma fractionation and biotechnology to make products safer, purer, and more available. The growth in investments in healthcare infrastructures especially in developing economies is enhancing access to superior hemostatic measures. Also, enabling government programmes, increased awareness of healthcare practitioners and increased integration of evidence based practice in transfusion are also increasing the market growth. All these factors will ensure that the demand of human fibrinogen concentrates remains high in the world.

Segment Insight

By Form

Lyophilized form has a considerable market share on the human fibrinogen concentrate market because it is extremely important in emergency and surgical practice where it is vital to have a quick intervention. It is a very appropriate agent to use in trauma cases, cardiac surgery and postpartum bleeding because it can be rapidly reconstituted and administered in minutes. The increase in shelf life and the ability to be stored without the complicated requirements of freezing would further increase the management of hospital inventory and decrease the wastage. Also, its clinical use is supported by standardized dosing and better safety profiles as it is more middle-of-the-night plasma-derived products. Ready-to-use in liquid form has limited clinical use because of limited shelf life and more stringent storage requirements whereas other formats are less preferred by clinical use because they require relatively more time to prepare.

By End User

A significant percentage of human fibrinogen concentrate market is represented by hospitals because of the large number of surgical procedures and critical care cases that are handled in the hospitals. Hospitals are the main trauma management centres and the ones involving intricate operations that demand quick hemostatic measures, with more than 300 million surgeries being done worldwide annually. Modern diagnostic devices and access to qualified medical personnel allow administering fibrinogen concentrates accurately and on time, which enhances the patient results. Also, hospitals have the ability to deal with the high-risk cases like the organ transplant and the cardiovascular surgeries. Minimally invasive surgical procedures are being proliferated in ambulatory surgical centers, which however, have fewer applications in severe bleeding conditions, whereas other healthcare facilities make fewer contributions because of the simplicity of the procedure.

By Indication

A human fibrinogen concentrate market is dominated by surgery as hemostasis is essential in the care of patients during and after the operation. During major surgery, e.g. heart surgery, orthopedic surgery, and hepatic surgery, the fibrinogen levels might go down at a rapid rate which predisposes one to excessive bleeding. Clinical practice has the focus on maintaining sufficient fibrinogen level to promote the formation of the clot and minimise the complications. The increased number of surgeries performed on a global scale still leads to the need of quick and dependable coagulation treatment. Fibrinogen concentrates are being used more of preference over the traditional blood components because preparation is fast, the doses are standard and there is less risk of complications as a result of transfusion. Congenital fibrinogen deficiency is a smaller segment as it is rare but it necessitates regular long-term treatment.

Outlook

According to recent forecasts, the human fibrinogen concentrate market is expected to grow steadily between 2026 and 2035, due to the rising cases of bleeding disorders, the number of surgical processes, and demand of effective therapies using hemostatic. The critical role of the fibrinogen concentrates in the management of trauma, postpartum bleeding, and complex surgical bleeding has been beneficial to the market. These products are easy to administer, standardize dose and are safer unlike traditional blood components, which improve clinical outcomes.

Regional Insights

The human fibrinogen concentrate market in Asia Pacific is expected to experience the highest growth rate, given the increasing healthcare infrastructures, increased knowledge of advanced hemostatic therapies, and the escalating rate of trauma and surgery occurrences. China, India, and Japan, among other countries, are spending much money in modernizing their health care, which is enhancing their access to critical care and emergency services. Europe is likely to record high growth rates because of the well-established health care systems, high concentration of plasma-derived products and favorable regulatory systems that safeguard safety and effectiveness. Reimbursement policies are also favorable in the region and the use of patient blood management programs is also increasing. In the meantime, North America is acclaimed as a mature but continuously growing market, which is backed by well-developed medical infrastructure, high surgical rates, and prevalence of evidence-based transfusion practices, as well as with continuous research, innovation, and positive regulatory support throughout the United States and Canada.

Report Scope

Recent Developments

• In July 2024, U.S. Food and Drug Administration granted approval to a human fibrinogen concentrate developed by Octapharma to treat acquired fibrinogen deficiency (AFD), a life-threatening condition that prevents the formation of clots in the blood and predisposes that patient to excessive hemorrhage. This was the first FDA-approved therapy with specific indication of AFD, which is a substantial step toward the targeted treatment of bleeding disorders.

List of the prominent players in the Human Fibrinogen Concentrate Market:

• CSL Behring

• Octapharma AG

• LFB Group

• Grifols S.A.

• Shanghai RAAS Blood Products Co. Ltd.

• Hualan Biological Engineering Inc.

• Harbin Pacific Biopharmaceutical Co. Ltd.

• Green Cross Corporation

• Shanghai XinXing Medical

• Jiangxi Boya Bio-Pharmaceutical Co. Ltd.

• Baxter International Inc.

• Kedrion Biopharma Inc.

• Biotest AG

• Sanquin Blood Supply Foundation

• China Biologic Products Holdings Inc.

• BPL (Bio Products Laboratory)

• Kamada Ltd.

• ProMetic Life Sciences Inc.

• Beijing Tiantan Biological Products Co. Ltd.

• Scripps Laboratories.

• Others

The Human Fibrinogen Concentrate Market is segmented as follows:

By Form

• Lyophilized

• Powder

• Liquid

By End User

• Hospitals

• Ambulatory Surgical Centers

• Others

By Indication

• Surgical Procedure

• Congenital Fibrinogen Deficiency

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America